Rhythm Pharmaceuticals Inc

RYTM remains in a Stage 2 advance underpinned by an active Parabola pattern and repaired EMAs, but price is extended well above the rising 9, 21, and 50 EMAs, with RSI and Options Score in extreme overbought territory and signs of upper‐wick fatigue at new highs. Short-term timing is unfavorable, so we will stalk for a shallow pullback into the rising EMA zone to align with the primary momentum trend.

• ↑Q1 2026 revenue hit $60 M, up 5% sequential in BBS sales
• ↑Gross margin ~84% for U.S. sales indicates strong cost control
• ↓Negative earnings yield raises valuation concerns